Total Funding
43
53
Total FundingGrant raised
Growth Score
-5 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
96495
Aldatu Biosciences is the leader in adaptive PCR diagnostics for global health and emerging diseases.
- Iain MacLeod: Co-Founder, CEO & CSOPast Role: Harvard T.H. Chan School of Public Health, Research Fellow
- Michael Henry: Chief Business OfficerPast Role: Centrillion Technologies, Senior Vice President and General Manager of Consumer Genomics
About the Company
Aldatu Biosciences specializes in adaptive PCR diagnostics for global health, epidemic prevention, preparedness, and response. Aldatu’s core strength lies in our unyielding motivation to deliver infectious disease diagnostics that enhance public health outcomes in low-and middle-income countries using PANDAA, our proprietary platform technology
that overcomes diagnostic challenges posed by viral genetic diversity. To date, Aldatu has secured >$20 million in non-dilutive funding from the NIH. The company maintains ISO 13485 certification, affirming compliance with rigorous international standards for medical device manufacturing.
